Wilson Sonsini’s Life Sciences Business Advisory team, which consists of experienced business leaders across a wide variety of life science disciplines, will be hosting a 1-hour session dedicated to exploring the ins and outs of venture capital investing. Whether you are an emerging biopharma company or have a breakthrough idea for a digital health app, understanding the intricacies of the life science venture capital environment is critical in setting your company up for success. Through this session, you will learn from experienced business leaders about the different types of life science investors, how to prepare for an outreach, how to develop a “killer” pitch deck, and much more.
Juliana Campbell
jcampbell@wsgr.comMatthew J. Meyer is chief business advisor for life sciences at Wilson Sonsini Goodrich & Rosati. Based in San Francisco, Matthew leads the firm's life science business advisory practice—a newly formed, innovative resource aimed at providing start-up and emerging life sciences companies with business insights, capabilities, and strategies to help them thrive and address some of their most challenging issues.
Dr. Craig Kenesky is an associate in the New York office of Wilson Sonsini Goodrich & Rosati. Craig applies his background in synthetic organic, medicinal, peptide, bioorganic, and computational chemistry to the prosecution of domestic and foreign patent applications, as well as due diligence, freedom to operate, portfolio development strategy, opinions, and IP counseling. Craig represents clients in numerous technology-focused industries, including the chemical, pharmaceutical, biotechnology, nanotechnology, diagnostic, neutriceutical, healthcare, process and manufacturing, energy, clean technology, biofuel, genomics, software, information technology, bioinformatics, scientific instrument, personalized medicine, and medical device sectors. He performs pre-transaction due diligence on behalf of both technology companies and venture capital groups, and he develops non-infringement and invalidity strategies for generic pharmaceutical companies.
Katharine (Kathy) Ku is the chief licensing advisor in the Palo Alto office of Wilson Sonsini Goodrich & Rosati. She is also a member of the technology transactions and the patents and innovations practice groups.